FDA issues Warning Letter to Indian Clinical Investigator over Bioequivalence Study Violations
The U.S. Food and Drug Administration (FDA) has issued a formal warning letter to a clinical investigator at Senthil Specialty Hospital in Pondicherry, India, citing significant violations of federal regulations during a clinical bioequivalence study




















